Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes

    ... has been linked to increased sensitivity to the drug lenalidomide . Phase II and III clinical trials have demonstrated the efficacy of lenalidomide in improving clinical outcomes of patients with del(5q) MDS, ...

    Research Article last updated 03/02/2015 - 2:11pm.

  2. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents

    ... treatments, including hypomethylating agents (HMAs), lenalidomide (LEN), and investigational drugs, may be used after ESA ...

    Research Article last updated 04/14/2017 - 9:09am.

  3. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion

    ... MDS patients achieve an erythroid response with lenalidomide in 25-30% of cases. Addition of erythropoiesis-stimulating ... identified in the diseased clone on response to lenalidomide and the drug effects on clonal evolution remain unknown. We ...

    Research Article last updated 04/29/2016 - 11:33am.

  4. Jane Massey’s Story

    ...   They decided to put me on an oral medication, lenalidomide (Revlimid®) and see if that helped my blood counts. Thus far ...

    Patient Chronicle last updated 04/11/2017 - 7:29am.

  5. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes

    ... (MDS) begins with assessment of karyotype and risk. Lenalidomide is approved for the treatment of patients who have ... only in the European Union. Mounting evidence suggests that lenalidomide is effective not only in reducing red blood cell (RBC) ...

    Research Article last updated 12/08/2015 - 1:06pm.

  6. Management of lower-risk myelodysplastic syndromes without del5q: Current approach and future trends

    ... agents (ESAs), immunosuppressive therapy (IST), lenalidomide and hypomethylating agents (HMAs). We also discuss the ...

    Research Article last updated 03/22/2017 - 9:46am.

  7. The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes

    ... Introduction: Lenalidomide is an IMiDs? oral immunomodulatory compound developed for the ... syndromes (MDS). Long-term continuous treatment with lenalidomide beyond first response may be important to optimize responses and ...

    Research Article last updated 11/16/2011 - 2:10pm.

  8. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide

    ... and decreased miR-145 and miR-146a expression. Lenalidomide is an immunomodulatory agent that selectively suppresses the ... of MDM2 with subsequent enhanced P53 degradation. Lenalidomide showed success in low- and intermediate-1-risk MDS as reported in ...

    Research Article last updated 04/17/2014 - 11:29am.

  9. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.

    ... Lenalidomide and azacitidine are active in MDS patients, and may ... malignant clone . A recent Phase I trial testing the lenalidomide and azacitidine combination yielded encouraging results; however, ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy: New Insights

    ... harboring TP53 mutation do not show a good response to lenalidomide therapy. In general, the results of this study show that ...

    Research Article last updated 02/01/2017 - 8:15am.